Details for Patent: 10,570,139

Which drugs does patent 10,570,139 protect, and when does it expire?

Patent 10,570,139 protects BRUKINSA and is included in one NDA.

This patent has thirty-two patent family members in twenty-six countries.

Summary for Patent: 10,570,139

Title:	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Abstract:	The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. ##STR00001##
Inventor(s):	Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN)
Assignee:	BEIGENE SWITZERLAND GMBH (Basel, CH)
Application Number:	15/969,864
Patent Claim Types: see list of patent claims	Use;

Recent additions to Drugs Protected by US Patent 10,570,139

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Beigene	BRUKINSA	zanubrutinib	CAPSULE	213217	Nov 14, 2019	RX	Yes						U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
Beigene	BRUKINSA	zanubrutinib	CAPSULE	213217	Nov 14, 2019	RX	Yes						U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Beigene	BRUKINSA	zanubrutinib	CAPSULE	213217	Nov 14, 2019	RX	Yes						U-2537	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Drugs Protected by US Patent 10,570,139

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes						FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Foreign Priority and PCT Information for Patent: 10,570,139

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/CN2013/074728	Apr 25, 2013

International Family Members for US Patent 10,570,139

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014256633
Brazil	112015025260
Canada	2902686